Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Lunsekimig by Sanofi for Asthma: Likelihood of Approval
Lunsekimig is under clinical development by Sanofi and currently in Phase II for Asthma. According to GlobalData, Phase II drugs...
Risk adjusted net present value: What is the current valuation of Sanofi's Lunsekimig?
Lunsekimig is a monoclonal antibody commercialized by Sanofi, with a leading Phase II program in Rhinosinusitis. According to Globaldata, it...
Risk adjusted net present value: What is the current valuation of Sanofi's Lunsekimig?
Lunsekimig is a monoclonal antibody commercialized by Sanofi, with a leading Phase II program in Asthma. According to Globaldata, it...